Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 702 across all filing types
Latest filing 2017-05-30 Director's Dealing
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-05-30 English
10-Q
Interim / Quarterly Report Q1 2017
2017-05-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated May 3, 2017, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2017. The text explicitly states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a notification of the earnings release. According to the 'MENU VS MEAL' rule, since the document is short (3421 characters) and primarily announces the release of a financial report (press release), it should be classified as an Earnings Release (ER) because the press release is the initial announcement of quarterly financial results. The 8-K filing is the vehicle for this announcement, and the press release is included as an exhibit. Therefore, the classification is Earnings Release (ER) with high confidence.
2017-05-03 English
DEF 14A
Proxy Solicitation & Information Statement
2017-04-19 English
FORM 3
Director's Dealing
2017-04-12 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 5, 2017, reporting the appointment of a new executive officer, William McVicar, as President of Research and Development. It details his background, employment agreement terms, compensation, and stock options. The key section is Item 5.02, which pertains to the departure or appointment of directors or certain officers. There is no financial data or report content, only an announcement of management change. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 5322 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2017-04-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.